Heterologous covid-19 vaccine intervention effect on reactogenicity

Public Sector Medical College, Rawalpindi0 个研究点目标入组 448 人开始时间: 待定最近更新: 2024年8月20日

试验速览

暂无简介。

•Adults 18 years of age or older
•- Men and women
•- Healthy or with stable chronic medical conditions specifically including asthma, stable HIV, hepatitis B virus, or hepatitis C virus infection, will be eligible for participation in the trial while all rest comorbidities will be an exclusion.
•- Must have history of 2 times homologous vaccine intervention of BBIBP-CorV vaccine.

•- People with known comorbidities (Diabetes, hypertension, heart diseases, chronic respiratory diseases
•like bronchiectasis, COPD etc) except those mentioned above in inclusion.
•- People who will have not received homologous vaccine two doses of BBIBP-CorV vaccine or those
•whose previous medical record of last 2 doses will be missing .
•- Difference between homologous vaccine and heterologous vaccine if less than 6 months
•- Pregnancy
•- History of flu or cough at that time
•- Medical history of COVID-19 at time of trial
•- On immunosuppressive therapy
•- Diagnosed with an immunocompromising condition

发起方

Public Sector Medical College, Rawalpindi